NCT06927297 2026-03-17
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
West China Hospital
Phase 1 Recruiting
Clinical Trials
411 trialsNCT07469982 2026-03-13
A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
Phase 1 Not yet recruiting
NCT05238792 2026-03-12
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
Children's National Research Institute
Phase 1 Recruiting
NCT06563375 2026-03-12
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02959463 2026-03-06
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05661201 2026-03-06
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Georgetown University
Phase 1 Recruiting
NCT04928508 2026-03-05
Okgyn1
University of Oklahoma
Phase 1 Recruiting
NCT03420963 2026-03-03
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06612645 2026-03-02
CMD03
Chulalongkorn University
Phase 1 Recruiting
NCT07443020 2026-03-02
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Not yet recruiting
NCT05100251 2026-02-17
Clinical Trial of WBC100 on Advanced Solid Tumor
Zhejiang University
Phase 1 Terminated
NCT07407985 2026-02-12
GK01IIT-TZ03
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Active not recruiting
NCT04166734 2026-02-04
MESO-PRIME
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT05478486 2026-02-04
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Godavari Biorefineries Limited
Phase 1 Completed
NCT07363369 2026-01-23
Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
West China Hospital
Phase 1 Not yet recruiting
NCT07356856 2026-01-21
Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1 Not yet recruiting
NCT02856425 2026-01-20
PEMBIB
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT07351903 2026-01-20
GUARDIAN-02
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Recruiting
NCT03997370 2026-01-14
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NRG Oncology
Phase 1 Recruiting
NCT03875287 2026-01-12
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT01591356 2026-01-07
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05650749 2025-12-29
GPC2
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT07100210 2025-12-29
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
West China Hospital
Phase 1 Recruiting
NCT01282697 2025-12-22
RAPIRI
University Hospital, Strasbourg, France
Phase 1 Completed
NCT06349837 2025-12-17
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase 1 Recruiting
NCT07285395 2025-12-16
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
NCT05521984 2025-12-08
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
Phase 1 Recruiting
NCT03760575 2025-12-04
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT07260513 2025-12-03
GH2616C102
Suzhou Genhouse Bio Co., Ltd.
Phase 1 Active not recruiting
NCT07257497 2025-12-02
Safety and Efficacy of Combining a Vitamin B6-Limited Diet With Immunotherapy in Solid Tumor Patients: A Clinical Study Protocol
West China Hospital
Phase 1 Not yet recruiting
NCT03618381 2025-11-20
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT04483778 2025-11-20
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT05038839 2025-11-20
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05608148 2025-11-18
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Kyushu University
Phase 1 Recruiting
NCT07098299 2025-11-06
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Barbara Ann Karmanos Cancer Institute
Phase 1 Recruiting
NCT04381806 2025-10-29
Phase I Study in Advanced Malignancies With 5-ALA
Fox Chase Cancer Center
Phase 1 Suspended
NCT03889795 2025-10-20
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
University of Toledo
Phase 1 Active not recruiting
NCT06576037 2025-10-15
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06066424 2025-10-14
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03191682 2025-09-25
A First-in-Human Study of PRL3-ZUMAB
National University Hospital, Singapore
Phase 1 Active not recruiting
NCT04162015 2025-09-12
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT07139067 2025-08-24
YK1101
Peking University
Phase 1 Recruiting
NCT03537690 2025-08-12
FID-007 in Treating Participants With Advanced Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT06372236 2025-08-12
UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors
Peking University
Phase 1 Completed
NCT07101549 2025-08-03
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1 Not yet recruiting
NCT02223923 2025-08-01
Patriot
Royal Marsden NHS Foundation Trust
Phase 1 Unknown
NCT02498912 2025-07-31
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04577326 2025-07-25
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03772561 2025-07-22
MEDIPAC
National University Hospital, Singapore
Phase 1 Recruiting